Biotechnology
Happiness Biotech Group Limited Announces Pricing of US$11 Million Firm Commitment Initial Public Offering
NANPING, China, Oct. 25, 2019 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company"), an innovativeChina-based nutraceutical and dietary supplements producer,announced today the pricing of a U.S. underwritten initial public offering ("Offering") of 2,000,000 ordinary shares at a price to...
Chugai Renews License to EpiVax's ISPRI In Silico Toolkit for Immunogenicity Assessment
PROVIDENCE, Rhode Island, Oct. 23, 2019 /PRNewswire/ -- Announced today, Chugai Pharmaceutical Co., Ltd. ("Chugai"), a member of the Roche Group, will extend the company's licensed access to theImmunogenicity Screening and Protein Reengineering Interface (ISPRI) toolkit developed by EpiVax, Inc. ...
TissueCypher® Further Validated to Accurately Risk Stratify Barrett's Esophagus Patients With Non-Dysplastic or Low-Grade Dysplasia Diagnoses: Findings Shared at Two Major GI Conferences
Data presented at ACG, UEGW illustrates the fourth independent validation of TissueCypher performance for risk stratifying non-dysplasticBarrett's esophagus (NDBE) patients; expands indication for testing low-grade dysplasia (LGD) PITTSBURGH, Oct. 23, 2019 /PRNewswire/ -- Cernostics, developer of...
New Horizon Health and Prenetics Establish Strategic Partnership to Launch ColoClear, the Chinese rival to ColoGuard, in Hong Kong and Southeast Asia
* ColoGuard, owned by Exact Sciences is one of the most successful genomics companies in the World, currently listed on the Nasdaq with a market cap ofUSD 12 Billion. * ColoClear will be the region's 1st non-invasive DNA stool test to screen for colorectal cancer at 92%,which can be done in t...
Innovent Biologics Announces Positive Updated Result from the Incyte-sponsored Phase II Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma
SUZHOU, China, Oct. 21, 2019 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent" or "the Company") (HKEX: 01801), a world-class biopharmaceutical company that develops and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, today ...
China Biologic Special Committee Retains Financial Advisor and Legal Counsel
BEIJING, Oct. 17, 2019 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced that the special committee (the "Special Committee") of the Company's board o...
GELITA & Geltor Sign Letter of Intent to Commercialize First Animal-Free Biodesigned Collagen for Dietary Supplements, a Market with Huge Growth Potential
LAS VEGAS, Oct. 17, 2019 /PRNewswire/ -- In the halls of the SupplySide West (SSW) Expo, officials from both GELITA and Geltor signed a letter of intent for developing, producing and marketing the first ingestible animal-free collagen proteins – to be launched in late 2020. In this arrangement, G...
MetGen Earns Acclaim from Frost & Sullivan for its Unique, Customized Enzyme Technologies, METNIN™ and ENZINE®
The technologies solve the industry's major pain points regarding the valorization of lignin, shorter technology development cycles, and customization of enzymes for different applications LONDON, Oct. 17, 2019 /PRNewswire/ -- Based on its recent analysis of the European industrial enzymes marke...
Sirtex Medical appoints Kevin R. Smith as Chief Executive Officer
Interim CEO unanimously chosen to lead global operations in patient-first oncology innovation WOBURN, Mass., Oct. 16, 2019 /PRNewswire/ -- Sirtex Medical, a leading manufacturer of targeted liver cancer therapies, today announced the appointment ofKevin R. Smith as Chief Executive Officer of Sir...
The 26th China Yangling Agricultural High-tech Achievements Expo will begin on October 22
YANGLING, China, Oct. 16, 2019 /PRNewswire/ -- On October 15, over ten international reporters, representing, among others, the European Pressphoto Agency, the Colpisa News Agency, the Korean Central News Agency, Radio-Television Slovenia, and the Republic of Korea's "Asian Economy", visited Yan...
Curiox Biosystems Achieves Commercialisation and Fund Raising Success in North Asia with the Support of Cornerstone Investor, ZIG Ventures
* CURIOX BIOSYSTEMS, is an A*STAR spinoff company, that develops bioinstrumentation solutions used in cell analysis and therapy for the pharmaceutical and biotech industries. The company has successfully penetrated theUSA, PRC, Korean and European markets and also secured a Series B funding of ...
Celemics Expedites Target Enrichment NGS Data Insights by Partnering With BlueBee on a Global Genomics Data Solution
SEOUL, South Korea, and RIJSWIJK, The Netherlands, Oct. 15, 2019 /PRNewswire/ -- Celemics, provider of NGS target enrichment kits and innovative sequencing platforms, announced today the release of a comprehensive NGS target enrichment workflow for clinical and translational research applications...
WuXi AppTec Research Service Division and BioSolveIT Introduce GalaXi®, a Vast New Chemical Space of Tangible Molecules
SHANGHAI and CAMBRIDGE, Massachusetts and SANKT AUGUSTIN, Germany, Oct. 10, 2019 /PRNewswire/ -- WuXi AppTec Research Service Division and BioSolveIT today launched a new virtual chemical space called GalaXi®. Largely built from WuXi AppTec's library of novel drug-like scaffolds, GalaXi® offers a...
CTFH and Insilico Medicine Enter Al Drug Discovery Collaboration Focused On Accelerating First-in-Class Therapeutics, Worth Up to $200 million
HONG KONG and NANJING, China, Oct. 9, 2019 /PRNewswire/ -- Insilico Medicine, a company developing an end-to-end drug discovery pipeline utilizing the latest advances in deep learning, has entered into a two-program AI drug discovery collaboration agreement with Jiangsu Chia Tai Fenghai Pharmaceu...
Datar Cancer Genetics Announces Positive Results With 42.9% Objective Response Rate, and 90.5% Disease Control Rate in Heavily Pre-treated Patients With Ultra-personalised Pan-cancer Treatment Protocol in the RESILIENT Trial
LONDON, MUMBAI, India and BAYREUTH, Germany, Oct. 9, 2019 /PRNewswire/ -- - RESILIENT Protocol captures Encyclopedic information from tumors and uses Artificial Intelligence (AI) to optimize treatments; - Objective Response and Disease Control Comparable to or better than most Immunotherapy opti...
Ascletis Appoints Former Novartis Global Head Dr. Handan He as Chief Scientific Officer
HANGZHOU, China and SHAOXING, China, Oct. 8, 2019 /PRNewswire/ -- Ascletis Pharma Inc. (1672.HK), an innovative R&D driven, commercial-stage biotechnology company addressing unmet medical needs in therapeutic areas including anti-viral, cancer and fatty liver diseases, announces today that Dr.Han...
Cross-industrial technologies make a splash in Asia Agri-Tech Expo in Taipei
TAIPEI, Oct. 5, 2019 /PRNewswire/ -- The Asia Agri-Tech Expo & Forum 2019 will take place at Taipei Nangang Exhibition Center Hall 1 fromOctober 31 to November 2. Organised by Informa Markets of Taiwan Office (UBM Taiwan), the tradeshow features innovative, eco-friendly and sustainable manufac...
Medicago's New Drug Submission accepted for scientific review by Health Canada: An important step for Medicago towards commercialization of its innovative influenza vaccine
QUEBEC CITY, Oct. 3, 2019 /PRNewswire/ -- Medicago, a biotechnology company and global leader in the development and production of plant-derived vaccines with headquarters inQuebec City, announces today that Health Canada accepted for scientific review its New Drug Submission (NDS) for a plant-ba...
AGC Biologics Appoints New Site Head/General Manager of Copenhagen, Denmark Operations
Jeffrey D. Mowery Named Site Head/General Manager BOTHELL, Washington, Oct. 1, 2019 /PRNewswire/ -- AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the appointment ofJeffery D. Mowery as Site Head/General Manager of theCopenhagen,...
Interleukin 11 Identified as New Therapeutic Target for Idiopathic Pulmonary Fibrosis
* Idiopathic pulmonary fibrosis (IPF) is a severe and fatal disease that causes lung damage and scarring * Blocking a protein called interleukin-11 (IL11), which is abnormally high in the lungs of patients with IPF, can reverse lung fibrosis and scarring in preclinical studies * Enleofen Bi...
Week's Top Stories
Most Reposted
Thailand Tops 2024 Consumer Review Awards by Agoda
[Picked up by 329 media titles]
2024-09-26 11:00WARHAMMER 40,000: SPACE MARINE VR - DEFENDERS OF AVARAX NOW AVAILABLE AT ZERO LATENCY VR VENUES WORLDWIDE
[Picked up by 314 media titles]
2024-09-26 00:00Advantech Unveils Expanded Singapore Office to Boost ASEAN Presence and Support AIoT Innovations with Strategic Partnerships
[Picked up by 312 media titles]
2024-09-23 13:37Circles Partners with Telkomsel, Providing an Advanced Software-as-a-Service (SaaS) Platform to Enhance Customer Digital Experience
[Picked up by 297 media titles]
2024-09-27 10:00RuggON Debuts at the Largest Mining Expo, MINExpo 2024 Showcasing Rugged Solutions for the Trillion-Dollar Mining Market
[Picked up by 294 media titles]
2024-09-23 22:00